Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

673 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins.
Schneider M, Witztum JL, Young SG, Ludwig EH, Miller ER, Tsimikas S, Curtiss LK, Marcovina SM, Taylor JM, Lawn RM, Innerarity TL, Pitas RE. Schneider M, et al. Among authors: miller er. J Lipid Res. 2005 Apr;46(4):769-78. doi: 10.1194/jlr.M400467-JLR200. Epub 2005 Jan 16. J Lipid Res. 2005. PMID: 15654123 Free article.
Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein.
Tsimikas S, Lau HK, Han KR, Shortal B, Miller ER, Segev A, Curtiss LK, Witztum JL, Strauss BH. Tsimikas S, et al. Among authors: miller er. Circulation. 2004 Jun 29;109(25):3164-70. doi: 10.1161/01.CIR.0000130844.01174.55. Epub 2004 Jun 7. Circulation. 2004. PMID: 15184281
High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial.
Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Tsimikas S, et al. Among authors: miller er. Circulation. 2004 Sep 14;110(11):1406-12. doi: 10.1161/01.CIR.0000141728.23033.B5. Epub 2004 Sep 7. Circulation. 2004. PMID: 15353498 Clinical Trial.
Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease.
Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, Witztum JL, Berger PB. Tsimikas S, et al. Among authors: miller er. N Engl J Med. 2005 Jul 7;353(1):46-57. doi: 10.1056/NEJMoa043175. N Engl J Med. 2005. PMID: 16000355 Free article.
Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study.
Tsimikas S, Kiechl S, Willeit J, Mayr M, Miller ER, Kronenberg F, Xu Q, Bergmark C, Weger S, Oberhollenzer F, Witztum JL. Tsimikas S, et al. Among authors: miller er. J Am Coll Cardiol. 2006 Jun 6;47(11):2219-28. doi: 10.1016/j.jacc.2006.03.001. Epub 2006 May 15. J Am Coll Cardiol. 2006. PMID: 16750687 Free article.
673 results